Immunomodulatory Effects of Probiotics on Th17-Mediated Immune Responses in Psoriasis: A Systematic Review and Meta-Analysis
DOI:
https://doi.org/10.37275/bsm.v10i6.1615Keywords:
Immunomodulation, Meta-analysis, Probiotics, Psoriasis, Th17Abstract
Background: Psoriasis is a chronic inflammatory skin disorder with increasing evidence supporting the role of the gut-skin axis in its pathogenesis. Recent studies suggest that probiotic supplementation may modulate Th17-mediated immune responses and improve clinical outcomes in psoriasis.
Methods: A systematic review and random-effects meta-analysis was conducted using PubMed, Scopus, Web of Science, and Cochrane Library databases (through February 2025). Randomised controlled trials evaluating probiotic supplementation in adult patients with psoriasis were included. The primary outcome was change in Psoriasis Area and Severity Index (PASI) score. Secondary outcomes included inflammatory markers (IL-6, CRP, IL-17) and immunological markers (Foxp3+ regulatory T cells, IL-10, TGF-β). Risk of bias was assessed using the Cochrane Risk of Bias tool (RoB 2), and evidence quality was evaluated using GRADE methodology.
Results: Five randomised controlled trials encompassing 268 participants (132 intervention, 136 control) were analysed. The pooled effect size for clinical outcomes (PASI) showed significant improvement favouring probiotic supplementation (Hedges' g = −0.8165; 95% confidence interval [CI], −1.6487 to −0.0483; p = 0.048; I² = 92.45%). Substantial heterogeneity was observed, with the Alshihmani 2025 pilot study demonstrating markedly larger effects on immunological markers (Hedges' g = −5.6963). Subgroup analysis revealed single-strain probiotics (pooled Hedges' g = −0.3487) had smaller effect sizes than multi-strain formulations (pooled Hedges' g = −3.6740). Publication bias assessment via funnel plot and Egger's regression showed no statistically significant asymmetry (p = 0.087).
Conclusion: Probiotic supplementation demonstrated statistically significant improvements in clinical outcomes and immunological markers in psoriasis. However, substantial heterogeneity and reliance on small trials limit certainty. The mechanistic evidence supporting gut-skin axis modulation warrants further investigation in adequately powered, long-term randomised controlled trials with standardised outcome measures and strain-specific analysis.
Authors
- Rindi Rosalina Fadly1*
- Usman Pato2
- Maya Savira3
- 1Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia
- 2Department of Food Science, Faculty of Agriculture, Universitas Riau, Pekanbaru, Indonesia
- 3Department of Microbiology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia
Corresponding author Rindi Rosalina Fadly — dr.rindirosalinafadly@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
